Louise Whitley

Louise is one of tranScrip’s Executive Directors working in medical affairs and pharmacovigilance with particular expertise in post-authorisation referral procedures and label updates. She has over 30 years of industry experience and previously worked for companies such as Lederle Laboratories, Wyeth and Parke Davis. As a consultant, Louise supported the regulatory, medical and pharmacovigilance departments of a wide range of companies.  In the 13 years Louise has been at tranScrip she has worked on pre- and post-licensing projects across many therapeutic areas.

Louise has extensive experience of medical affairs, pharmacovigilance, medical and regulatory writing, medical information and staff training. She has provided training and mentoring for medical staff and sales representatives. Her product launch experience includes lansoprazole (Zoton), venlafaxine (Efexor) and atorvastatin (Lipitor).

Louise is a pharmacist with an MSc in clinical pharmacy. She started her career in hospital and community pharmacy, then worked in an NHS regional drug information centre and as a practice pharmacist developing clinical treatment guidelines and conducting prescribing audits. Louise spent two years as a senior editor of the British National Formulary (BNF) where she was responsible for chapters on the cardiovascular system, vaccines, malignant disease and immunosuppression. She continued to work for the BNF, BNF for Children, Dental Practitioners’ Formulary and WHO Model Formulary on a variety of projects over subsequent years.

Louise was a member of BIA’s Genomics Advisory Committee.